A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate preliminary safety and efficacy of TP-0184 to treat anemia when
administered to adult patients with Revised International Prognostic Scoring System (IPSS-R)
low or intermediate risk MDS. The recommended Phase 2 dose (RP2D) will be determined by the
maximum tolerated dose (MTD) or maximum administered dose (MAD) in the Phase 1 portion of the
study.